



29 December 2022

## **Changes to various ASX announcements of 23 December 2022**

### ***Rights Issue Timetable - Change to Dispatch Date***

**Opyl Limited (ASX:OPL)** refers to the following announcement released with the ASX on 23 December 2022:

- Opyl completes Placement and launches Rights Issue
- Opyl Opens Rights Issue
- Rights Issue Offer Booklet

In relation to the above three (3) announcements, the Company wishes to change the date reflected in the above announcements for the Despatch of the Offer Document and online Entitlement & Acceptance Form to Eligible Shareholders from **Tuesday 3 January 2023** to **Wednesday 4 January 2023**.

### ***Placement Timetable - Change to Issue Date***

In addition to the above, Opyl refers to the updated Appendix 3B (Update - Proposed issue of securities – OPL) announcement released with the ASX on 23 December 2022 in respect of the Placement the company completed.

The Company wishes to change the proposed issue date noted at 7C.1 from **Thursday 29 December 2022** to **Tuesday 3 January 2023**.

The Board has authorised this announcement for release to the ASX.

**- ENDS-**

For media and investor enquiries: [info@opyl.ai](mailto:info@opyl.ai)

For clinical trial recruitment enquiries: [info@opin.ai](mailto:info@opin.ai)

[www.opyl.ai](http://www.opyl.ai)

[www.opin.ai](http://www.opin.ai)

Opyl is a new generation Australian digital health company that applies artificial intelligence to improving clinical trials. Our platforms make clinical trials more efficient and easier to access, giving patients more options and saving medical researchers time and money.

Our key offering for biopharma, medtech, government and healthcare organisations:

- clinical trial recruitment solutions – Opin.ai
- clinical trial predictive analytics and protocol design – TrialKey
- deep social media insights and analysis – Social Insights

Follow Opyl on Twitter (@Opylai), LinkedIn and Facebook